Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221007511> ?p ?o ?g. }
- W4221007511 endingPage "103663" @default.
- W4221007511 startingPage "103663" @default.
- W4221007511 abstract "The long-term remissions induced by immune-checkpoint inhibitors (ICIs) in many types of cancers have opened up the possibility of a broader use of immunotherapy in less immunogenic but genetically heterogeneous tumours. Regarding metastatic colorectal cancer (mCRC), in first-line setting, pembrolizumab has been approved as preferred option and nivolumab, alone or in combination with ipilimumab as alternative option for patients with mismatch-repair-deficient and microsatellite instability-high (dMMR/MSI-H) disease, independently of their eligibility for intensive chemotherapy. In subsequent lines, both these immunotherapeutic regimens (e.g., pembrolizumab and nivolumab+/-ipilimumab) as well as dostarlimab-gxly are currently recommended for patients with dMMR/MSI-H chemo-resistant mCRC who have not previously received an ICI. Beginning from the rationale behind the immune-mediated interplay in the dMMR/MSI-H bowel microenvironment, we provide here an update on the evolution status of all available, approved or not, ICIs in mCRC, describing their efficacy and toxicity profile with an emphasis on the pivotal trials supporting current colorectal indications. For each ICI agent, the results from combinations under investigation, particularly for those being upgraded in clinical phasing, the perspectives but also the limitations of main ongoing trials are thoroughly discussed. In the close future, upcoming data are expected to confirm the clinical benefit of ICIs and to further expand their role in mCRC." @default.
- W4221007511 created "2022-04-03" @default.
- W4221007511 creator A5034487496 @default.
- W4221007511 creator A5050395315 @default.
- W4221007511 creator A5056276465 @default.
- W4221007511 creator A5074458672 @default.
- W4221007511 creator A5082870009 @default.
- W4221007511 creator A5090633646 @default.
- W4221007511 creator A5091615051 @default.
- W4221007511 date "2022-05-01" @default.
- W4221007511 modified "2023-10-06" @default.
- W4221007511 title "Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update" @default.
- W4221007511 cites W1538930506 @default.
- W4221007511 cites W1544851750 @default.
- W4221007511 cites W1663153674 @default.
- W4221007511 cites W1785873212 @default.
- W4221007511 cites W1820495241 @default.
- W4221007511 cites W1859257957 @default.
- W4221007511 cites W1933761723 @default.
- W4221007511 cites W1934094702 @default.
- W4221007511 cites W1940241680 @default.
- W4221007511 cites W2006924771 @default.
- W4221007511 cites W2010121426 @default.
- W4221007511 cites W2013475854 @default.
- W4221007511 cites W2022208959 @default.
- W4221007511 cites W2033689666 @default.
- W4221007511 cites W2049553585 @default.
- W4221007511 cites W2084799522 @default.
- W4221007511 cites W2090109598 @default.
- W4221007511 cites W2091103707 @default.
- W4221007511 cites W2091755519 @default.
- W4221007511 cites W2094390470 @default.
- W4221007511 cites W2096151993 @default.
- W4221007511 cites W2117692326 @default.
- W4221007511 cites W2121820529 @default.
- W4221007511 cites W2122940327 @default.
- W4221007511 cites W2123636561 @default.
- W4221007511 cites W2132105937 @default.
- W4221007511 cites W2140875987 @default.
- W4221007511 cites W2142300779 @default.
- W4221007511 cites W2147698761 @default.
- W4221007511 cites W2147834058 @default.
- W4221007511 cites W2148300747 @default.
- W4221007511 cites W2150633526 @default.
- W4221007511 cites W2154697747 @default.
- W4221007511 cites W2159064822 @default.
- W4221007511 cites W2160834915 @default.
- W4221007511 cites W2171190137 @default.
- W4221007511 cites W2252550602 @default.
- W4221007511 cites W2261057385 @default.
- W4221007511 cites W2262414037 @default.
- W4221007511 cites W2285547302 @default.
- W4221007511 cites W2289851792 @default.
- W4221007511 cites W2346775047 @default.
- W4221007511 cites W2413897266 @default.
- W4221007511 cites W2474527756 @default.
- W4221007511 cites W2502448841 @default.
- W4221007511 cites W2510679674 @default.
- W4221007511 cites W2597811717 @default.
- W4221007511 cites W2598253740 @default.
- W4221007511 cites W2600889039 @default.
- W4221007511 cites W2611196568 @default.
- W4221007511 cites W2622499649 @default.
- W4221007511 cites W2739132742 @default.
- W4221007511 cites W2750299794 @default.
- W4221007511 cites W2762239861 @default.
- W4221007511 cites W2763756555 @default.
- W4221007511 cites W2765355923 @default.
- W4221007511 cites W2769370230 @default.
- W4221007511 cites W2779221466 @default.
- W4221007511 cites W2781642641 @default.
- W4221007511 cites W2784868445 @default.
- W4221007511 cites W2794590332 @default.
- W4221007511 cites W2809907085 @default.
- W4221007511 cites W2888302003 @default.
- W4221007511 cites W2890224843 @default.
- W4221007511 cites W2891102464 @default.
- W4221007511 cites W2891267398 @default.
- W4221007511 cites W2897257669 @default.
- W4221007511 cites W2901793863 @default.
- W4221007511 cites W2902690248 @default.
- W4221007511 cites W2904251687 @default.
- W4221007511 cites W2907290230 @default.
- W4221007511 cites W2909132011 @default.
- W4221007511 cites W2911267838 @default.
- W4221007511 cites W2920863623 @default.
- W4221007511 cites W2929513598 @default.
- W4221007511 cites W2938645074 @default.
- W4221007511 cites W2965445854 @default.
- W4221007511 cites W2967681225 @default.
- W4221007511 cites W2968331746 @default.
- W4221007511 cites W2969381967 @default.
- W4221007511 cites W2978397325 @default.
- W4221007511 cites W2978878045 @default.
- W4221007511 cites W2982425966 @default.
- W4221007511 cites W2983284890 @default.
- W4221007511 cites W2998727921 @default.
- W4221007511 cites W3002834606 @default.